News and Insights

The latest news and insights from Genoa Healthcare.
  • 340B

340B made easy: 5 traits to look for in a contract pharmacy partner

The 340B Drug Pricing Program helps participating organizations – or covered entities – use savings on prescription drug costs to offer more comprehensive services and care for more eligible patients....

  • Sep 12th, 2023
  • 340B

The 340B Program information you’re looking for

For qualified clinics and organizations, the 340B Drug Pricing Program offers savings on prescription drug costs, helping boost offerings and outcomes for people who need it most. Wondering if your...

  • Sep 5th, 2023
  • Partner Highlights
  • Pharmacy Openings

Announcing seven new pharmacy openings!

We’re excited to announce the opening of seven pharmacies last month. We welcome all new pharmacy staff to the team and are excited to partner with these organizations to serve...

  • Sep 5th, 2023
  • Behavioral Health
  • Clinical Insights
  • Treatment

September 2023 drug trend report

Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market. Brand name drug launches* Brixadi™ Zurzuvae™ (zuranolone) Generic drug...

  • Sep 1st, 2023
  • Genoa in the News

Genoa Healthcare featured in recent article about the important role of pharmacists

In a recent article featuring Genoa Healthcare, Chain Drug Review highlighted the important role pharmacy teams play in providing personalized, compassionate care to meet the needs of medically underserved communities....

  • Aug 30th, 2023
  • Behavioral Health
  • Clinical Insights

Caring for those with treatment-resistant depression

Genoa Healthcare® can partner with you to improve outcomes for your patients living with TRD. Connect with us to get started today. One in three adults with major depressive disorder...

  • Aug 9th, 2023
  • Behavioral Health
  • Clinical Insights
  • Treatment

4 things to know about Spravato® (Intranasal esketamine)

Looking for information on Spravato®? Here are four things you should know. Spravato®: What, why and how? Spravato® is an FDA-approved nasal spray indicated for the treatment of treatment-resistant depression...

  • Aug 9th, 2023
  • Behavioral Health
  • Clinical Insights
  • Treatment

August 2023 drug trend report

Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market. Brand name drug launches* Uzedy Abilify Asimtuffii Brixadi Generic...

  • Aug 2nd, 2023
  • Behavioral Health
  • Clinical Insights
  • Treatment

Currently available and emerging therapy options for treatment-resistant depression

Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...

  • Aug 2nd, 2023
  • Partner Highlights
  • Pharmacy Openings

Announcing four new pharmacy openings!

We’re excited to announce the opening of four pharmacies last month. We welcome all new pharmacy staff to the team and are excited to partner with these organizations to serve...

  • Jul 7th, 2023